Taich Adam
Taich Adam, CFO, reported an open-market or private sale at 10x Genomics, Inc. involving 15098.000000 shares for an estimated $369017.77. Reported holdings after the transaction were 379898.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- May 22, 2026
- Filing date
- May 27, 2026
How reported position traded is calculated
Shares sold ÷ (holdings after + shares sold). Estimated position before: 394,996 shares.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
TXG price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- Sell Code S
- Identifier
- 0001610717-26-000162 Class A Common Stock
- Transaction date
- May 22, 2026 Filed May 27, 2026, 09:55 PM · 5d delay
- Shares
- 15,098 sh $24.44 per share
- Estimated value
- -$369k Computed from shares × price
- Holdings after
- 379,898 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
+6 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Chief Financial Officer
- F1
The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
0 other transactions
0 recent txs